Form 4: Cyclo Therapeutics Director Acquires Shares in Lieu of Cash Compensation

Cyclo Therapeutics director Randall M. Toig acquired 20,067 shares of common stock in lieu of cash compensation for the third quarter of 2024.

Summary

• Randall M. Toig, a director at Cyclo Therapeutics, Inc., acquired 20,067 shares of common stock on November 15, 2024.
• These shares were granted in lieu of cash compensation for his service as a non-employee director.
• The grant reflects compensation for the third quarter of 2024.
• The number of shares was calculated based on a closing price of $0.66 per share on November 14, 2024.
• Following this transaction, Mr. Toig directly owns 145,826 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of a director receiving stock compensation, which is generally viewed as a positive sign of alignment with shareholder interests. There are no negative implications.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• The use of shares in lieu of cash compensation can be seen as a positive for the company's cash flow.

Industry Context

This is a standard transaction for a director receiving compensation in the form of company stock, which is common practice in publicly traded companies.

Comparison to Industry Standards

• Many publicly traded companies use stock grants as part of director compensation packages.
• The practice of granting shares in lieu of cash is a common method to align director interests with shareholder value.
• The specific number of shares and valuation are typical for a company of this size and stage.

Stakeholder Impact

• Shareholders may view this as a positive sign of director commitment.
• The transaction has a neutral impact on employees, customers, suppliers, and creditors.

Key Dates

Keywords

Cyclo Therapeutics, Director, Share Acquisition, Stock Grant, Compensation, Form 4, Insider Trading